GLP-1 Peptide Analogues for Sustaining Synaptic LTP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Impaired long-term potentiation (LTP) of synaptic transmission is associated with cognitive deficits in neurological disorders, including age-related memory impairment and neurodegenerative diseases like Alzheimer's, where existing treatments fail to effectively sustain or enhance LTP.
Innovation Solution
A peptide analogue of glucagon-like peptide-1 (7-36) with specific amino acid substitutions or modifications, such as at positions 26 and 34, is used to treat and prophylaxis neurological disorders by enhancing LTP, including the use of Liraglutide, which retains biological activity and is resistant to degradation by dipeptidyl peptidase IV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for neurological disorders, then treatment is provided, but they fail to effectively sustain or enhance LTP
Solution Approach 1:
The patent modifies the GLP-1 peptide structure by introducing specific amino acid substitutions (Ala8, Val8, Asp7, Pro9) and fatty acid acylation at Lys26 to create analogues with enhanced and sustained LTP-enhancing activity. These parameter changes in the peptide structure resolve the contradiction by making the treatment more effective at sustaining LTP while maintaining cognitive function.
Solution Approach 2:
The invention creates composite peptide structures by combining GLP-1 with fatty acid chains (such as myristoyl, palmitoyl, or stearoyl groups) through acylation. This composite approach enhances membrane permeability and receptor binding, thereby improving LTP sustainability and cognitive function maintenance beyond what existing treatments achieve.
2Reliability
If GLP-1 is used to enhance LTP, then synaptic transmission is improved, but the peptide is degraded by dipeptidyl peptidase IV
Solution Approach 1:
The patent introduces N-terminal modifications including acetylation, pyroglutamation, or D-amino acid substitution at position 7, which protect the peptide from DPP-IV degradation. These parameter changes preserve the LTP-enhancing activity while extending the duration of action by preventing enzymatic breakdown.
Solution Approach 2:
By protecting against degradation through structural modifications, the peptide maintains continuous LTP-enhancing activity over extended periods. The fatty acid acylation and N-terminal modifications ensure sustained presence in the brain, providing continuous therapeutic effect rather than transient action.
3Ease of operation
If fatty acid acylation is added to GLP-1, then membrane permeability is enhanced, but molecular weight increases
Solution Approach 1:
The patent strategically adds fatty acid chains (myristoyl C14, palmitoyl C16, or stearoyl C18) at the Lys26 position, which enhances membrane permeability and brain uptake. While this does increase molecular weight, the controlled addition of specific fatty acid lengths optimizes the balance between permeability enhancement and molecular size constraints.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age.